Ira Duarte Biography and Net Worth

Executive Vice President, Chief Financial Officer of Heron Therapeutics

Ira Duarte joined Heron as Executive Vice President, Chief Financial Officer in June 2023. Ms. Duarte brings significant experience and expertise in financial leadership to Heron. Prior to joining Heron, Ms. Duarte served in financial leadership roles from 2016 to 2023, most recently as Chief Financial Officer, at Veloxis Pharmaceuticals, Inc., a fully integrated specialty pharmaceutical company. Prior to that, Ms. Duarte served as the Corporate Controller at BioDelivery Sciences, Inc. from 2014 to 2016, and from 2009 to 2014 she was Senior Director of Corporate Finance for Chiesi USA, Inc. and Director of Accounting and Financial Planning for Cornerstone Therapeutics, Inc., where she was a core member of the team that guided the sale of Cornerstone Therapeutics, Inc. to Chiesi Farmaceutici S.p.A. Ms. Duarte previously held various roles from Staff to Senior Manager at Ernst & Young Global Limited. Ms. Duarte currently serves on the board of directors of TerrAscend Corporation and has since December 2022. Ms. Duarte is a Certified Public Accountant and holds a B.S. in Accounting from Florida Atlantic University.

What is Ira Duarte's net worth?: The estimated net worth of Ira Duarte is at least $111.35 thousand as of November 16th, 2023. Ms. Duarte owns 85,000 shares of Heron Therapeutics stock worth more than $111,350 as of December 5th. This net worth approximation does not reflect any other assets that Ms. Duarte may own. Learn More about Ira Duarte's net worth.
How old is Ira Duarte?: Ms. Duarte is currently 55 years old. There are 4 older executives and no younger executives at Heron Therapeutics. Learn More on Ira Duarte's age.
How do I contact Ira Duarte?: The corporate mailing address for Ms. Duarte and other Heron Therapeutics executives is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. Heron Therapeutics can also be reached via phone at (858) 251-4400 and via email at [email protected]. Learn More on Ira Duarte's contact information.
Has Ira Duarte been buying or selling shares of Heron Therapeutics?: Ira Duarte has not been actively trading shares of Heron Therapeutics within the last three months. Most recently, on Thursday, November 16th, Ira Duarte bought 85,000 shares of Heron Therapeutics stock. The stock was acquired at an average cost of $0.89 per share, with a total value of $75,650.00. Following the completion of the transaction, the chief financial officer now directly owns 85,000 shares of the company's stock, valued at $75,650. Learn More on Ira Duarte's trading history.
Who are Heron Therapeutics' active insiders?: Heron Therapeutics' insider roster includes Craig Collard (CEO), Ira Duarte (Executive Vice President, Chief Financial Officer), William Forbes (Executive Vice President, Chief Development Officer), Craig Johnson (Director), Kimberly Manhard (EVP), Adam Morgan (Director), and Christian Waage (Director). Learn More on Heron Therapeutics' active insiders.
Are insiders buying or selling shares of Heron Therapeutics?: In the last year, Heron Therapeutics insiders bought shares 2 times. They purchased a total of 4,153,771 shares worth more than $6,230,656.50. The most recent insider tranaction occured on August, 8th when Director Adam Morgan bought 1,766,546 shares worth more than $2,649,819.00. Insiders at Heron Therapeutics own 5.9% of the company. Learn More about insider trades at Heron Therapeutics.
Information on this page was last updated on 8/8/2025.

Ira Duarte Insider Trading History at Heron Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/16/2023	Buy	85,000	$0.89	$75,650.00	85,000

Ira Duarte Buying and Selling Activity at Heron Therapeutics

Heron Therapeutics Company Overview

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Today's Range

Now: $1.31

$1.20

$1.32

50 Day Range

MA: $1.20

$1.06

$1.35

2 Week Range

Now: $1.31

$1.00

$2.68

Volume

2,743,711 shs

Average Volume

1,823,356 shs

Market Capitalization

$240.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34

Ira Duarte Biography and Net Worth

What is Ira Duarte's net worth?

How old is Ira Duarte?

How do I contact Ira Duarte?

Has Ira Duarte been buying or selling shares of Heron Therapeutics?

Who are Heron Therapeutics' active insiders?

Are insiders buying or selling shares of Heron Therapeutics?